| ［1］ |
Van Baelen K，Geukens T，Maetens M，et al. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer ［J］. Ann Oncol, 2022, 33（8）：769-785.
|
| ［2］ |
Li CI，Uribe DJ，Daling JR. Clinical characteristics of different histologic types of breast cancer ［J］. Br J Cancer，2005，93（9）：1046-1052.
|
| ［3］ |
Pestalozzi BC，Zahrieh D，Mallon E，et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast：combined results of 15 International Breast Cancer Study Group clinical trials ［J］. J Clin Oncol，2008，26（18）：3006-3014.
|
| ［4］ |
Mathew A，Rajagopal PS，Villgran V，et al. Distinct pattern of metastases in patients with invasive lobular carcinoma of the breast ［J］. Geburtshilfe Frauenheilkd，2017，77（6）：660-666.
|
| ［5］ |
He H，Gonzalez A，Robinson E，et al. Distant metastatic disease manifestations in infiltrating lobular carcinoma of the breast ［J］. AJR Am J Roentgenol，2014，202（5）：1140-1148.
|
| ［6］ |
Johnson K，Sarma D，Hwang ES. Lobular breast cancer series：imaging ［J］. Breast Cancer Res，2015，17（1）：94.
|
| ［7］ |
Biglia N，Mariani L，Sgro L，et al. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy：implications for diagnosis，surgical and medical treatment ［J］. Endocr Relat Cancer，2007，14（3）：549-567.
|
| ［8］ |
Rebolj M，Assi V，Brentnall A，et al. Addition of ultrasound to mammography in the case of dense breast tissue：systematic review and meta-analysis ［J］. Br J Cancer，2018，118（12）：1559-1570.
|
| ［9］ |
Selvi V，Nori J，Meattini I，et al. Role of magnetic resonance imaging in the preoperative staging and work-up of patients affected by invasive lobular carcinoma or invasive ductolobular carcinoma ［J］. Biomed Res Int，2018，1569060.
|
| ［10］ |
Tan PH，Ellis I，Allison K，et al. The 2019 World Health Organization classification of tumours of the breast ［J］. Histopathology，2020，77（2）：181-185.
|
| ［11］ |
Desmedt C，Zoppoli G，Gundem G，et al. Genomic characterization of primary invasive lobular breast cancer ［J］. J Clin Oncol，2016，34（16）：1872-1881.
|
| ［12］ |
Christgen M，Steinemann D，Kühnle E，et al. Lobular breast cancer：clinical，molecular and morphological characteristics ［J］. Pathol Res Pract，2016，212（7）：583-597.
|
| ［13］ |
De Schepper M，Vincent-Salomon A，Christgen M，et al. Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer ［J］. Mod Pathol，2022，35（12）：1812-1820.
|
| ［14］ |
Tenhagen M，Klarenbeek S，Braumuller TM，et al. p120-Catenin is critical for the development of invasive lobular carcinoma in mice ［J］. J Mammary Gland Biol Neoplasia，2016，21（3/4）：81-88.
|
| ［15］ |
van de Ven RA，Tenhagen M，Meuleman W，et al. Nuclear p120-catenin regulates the anoikis resistance of mouse lobular breast cancer cells through Kaiso-dependent Wnt11 expression ［J］. Dis Model Mech，2015，8（4）：373-384.
|
| ［16］ |
Christgen M，Gluz O，Harbeck N，et al. Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer ［J］. Cancer，2020，126（22）：4847-4858.
|
| ［17］ |
Christgen M，Kandt LD，Antonopoulos W，et al. Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma ［J］. J Pathol Clin Res，2022，8（2）：191-205.
|
| ［18］ |
De la Cruz Ku G，Karamchandani M，Chambergo-Michilot D，et al. Does breast-conserving surgery with radiotherapy have a better survival than mastectomy？ A meta-analysis of more than 1，500，000 patients ［J］. Ann Surg Oncol，2022，29（10）：6163-6188.
|
| ［19］ |
Vila J，Gandini S，Gentilini O. Overall survival according to type of surgery in young（≤40 years）early breast cancer patients：a systematic meta-analysis comparing breast-conserving surgery versus mastectomy ［J］. Breast，2015，24（3）：175-181.
|
| ［20］ |
Fodor J，Major T，Tóth J，et al. Comparison of mastectomy with breast-conserving surgery in invasive lobular carcinoma：15-year results ［J］. Rep Pract Oncol Radiother，2011，16（6）：227-231.
|
| ［21］ |
Yu TJ，Liu YY，Hu X，et al. Survival following breast-conserving therapy is equal to that following mastectomy in young women with early-stage invasive lobular carcinoma ［J］. Eur J Surg Oncol，2018，44（11）：1703-1707.
|
| ［22］ |
Vo TN，Meric-Bernstam F，Yi M，et al. Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma ［J］. Am J Surg，2006，192（4）：552-555.
|
| ［23］ |
Santiago RJ，Harris EE，Qin L，et al. Similar long-term results of breast-conservation treatment for stage Ⅰ and Ⅱ invasive lobular carcinoma compared with invasive ductal carcinoma of the breast：the University of Pennsylvania experience ［J］. Cancer，2005，103（12）：2447-2454.
|
| ［24］ |
Wang K，Zhu GQ，Shi Y，et al. Long-term survival differences between T1-2 invasive lobular breast cancer and corresponding ductal carcinoma after breast-conserving surgery：a propensity-scored matched longitudinal cohort study ［J］. Clin Breast Cancer，2019，19（1）：e101-e115.
|
| ［25］ |
Chagpar AB，Killelea BK，Tsangaris TN，et al. A randomized controlled trial of cavity shave margins in breast cancer ［J］. N Engl J Med，2015，373（6）：503-510.
|
| ［26］ |
Piper ML，Wong J，Fahrner-Scott K，et al. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast ［J］. NPJ Breast Cancer，2019，5：29.
|
| ［27］ |
Biglia N，Maggiorotto F，Liberale V，et al. Clinical-pathologic features，long term-outcome and surgical treatment in a large series of patients with invasive lobular carcinoma（ILC） and invasive ductal carcinoma（IDC） ［J］. Eur J Surg Oncol，2013，39（5）：455-460.
|
| ［28］ |
Kim SH，Cha ES，Park CS，et al. Imaging features of invasive lobular carcinoma：comparison with invasive ductal carcinoma ［J］. Jpn J Radiol，2011，29（7）：475-482.
|
| ［29］ |
Straver ME，Rutgers EJ，Rodenhuis S，et al. The relevance of breast cancer subtypes in the outcome of neoadjuvantchemotherapy ［J］. Ann Surg Oncol，2010，17（9）：2411-2418.
|
| ［30］ |
Tubiana-Hulin M，Stevens D，Lasry S，et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas：a retrospective study on 860 patients from one iIBC-NSTitution ［J］. Ann Oncol，2006，17（8）：1228-1233.
|
| ［31］ |
Van Wyhe RD，Caudle AS，Shaitelman SF，et al. A component of lobular carcinoma in clinically lymph node-negative patients predicts for an increased likelihood of upstaging to pathologic stage Ⅲ breast cancer ［J］. Adv Radiat Oncol，2018，3（3）：252-257.
|
| ［32］ |
Whelan TJ，Julian JA，Berrang TS，et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer（RAPID）：a randomised controlled trial ［J］. Lancet，2019，394（10215）：2165-2172.
|
| ［33］ |
Schäfer R，Strnad V，Polgár C，et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery（GEC-ESTRO）：5-year results of a randomised，phase 3 trial ［J］. Lancet Oncol，2018，19（6）：834-844.
|
| ［34］ |
Cardoso F，Kyriakides S，Ohno S，et al. Early breast cancer：ESMO clinical practice guidelines for diagnosis，treatment and follow-up ［J］. Ann Oncol，2019，30（8）：1194-1220.
|
| ［35］ |
Mills MN，Russo NW，Fahey M，et al. Increased risk for ipsilateral breast tumor recurrence in invasive lobular carcinoma after accelerated partial breast irradiation brachytherapy ［J］. Oncologist，2021，26（11）：e1931-e1938.
|
| ［36］ |
Stecklein SR，Shen X，Mitchell MP. Post-mastectomy radiation therapy for invasive lobular carcinoma：a comparative utilization and outcomes study ［J］. Clin Breast Cancer，2016，16（4）：319-326.
|
| ［37］ |
Trapani D，Gandini S，Corti C，et al. Benefit of adjuvant chemotherapy in patients with lobular breast cancer：a systematic review of the literature and meta-analysis ［J］. Cancer Treat Rev，2021，97：102205.
|
| ［38］ |
Kizy S，Huang JL，Marmor S，et al. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast ［J］. Breast Cancer Res Treat，2017，165（3）：757-763.
|
| ［39］ |
Chen XH，Zhang WW，Wang J，et al. 21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer ［J］. Biomark Med，2019，13（2）：83-93.
|
| ［40］ |
de Nonneville A，Jauffret C，Gonçalves A，et al. Adjuvant chemotherapy in lobular carcinoma of the breast：a clinicopathological score identifies high-risk patient with survival benefit ［J］. Breast Cancer Res Treat，2019，175（2）：379-387.
|
| ［41］ |
de Gregorio A，Janni W，Friedl TWP，et al. The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C ［J］. Br J Cancer，2022，126（12）：1715-1724.
|
| ［42］ |
Tsung K，Grobmyer SR，Tu C，et al. Neoadjuvant systemic therapy in invasive lobular breast cancer：is it indicated？ ［J］. Am J Surg，2018，215（3）：509-512.
|
| ［43］ |
Petrelli F，Barni S. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast：a meta-analysis of published trials including 1，764 lobular breast cancer ［J］. Breast Cancer Res Treat，2013，142（2）：227-235.
|
| ［44］ |
Lips EH，Mukhtar RA，Yau C，et al. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer ［J］. Breast Cancer Res Treat，2012，136（1）：35-43.
|
| ［45］ |
Delpech Y，Coutant C，Hsu L，et al. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas ［J］. Br J Cancer，2013，108（2）：285-291.
|
| ［46］ |
Cristofanilli M，Gonzalez-Angulo A，Sneige N，et al. Invasive lobular carcinoma classic type：response to primary chemotherapy and survival outcomes ［J］. J Clin Oncol，2005，23（1）：41-48.
|
| ［47］ |
Timbres J，Moss C，Mera A，et al. Survival outcomes in invasive lobular carcinoma compared to oestrogen receptor-positive invasive ductal carcinoma ［J］. Cancers（Basel），2021，13（12）:3036.
|
| ［48］ |
Riba LA，Russell T，Alapati A，et al. Characterizing response to neoadjuvant chemotherapy in invasive lobular breast carcinoma ［J］. J Surg Res，2019，233：436-443.
|
| ［49］ |
Loibl S，Volz C，Mau C，et al. Response and prognosis after neoadjuvant chemotherapy in 1，051 patients with infiltrating lobular breast carcinoma ［J］. Breast Cancer Res Treat，2014，144（1）：153-162.
|
| ［50］ |
Pérez-Garcia J，Cortés J，Metzger Filho O. Efficacy of single-agent chemotherapy for patients with advanced invasive lobular carcinoma：a pooled analysis from three clinical trials ［J］. Oncologist，2019，24（8）：1041-1047.
|
| ［51］ |
Thijssen S，Wildiers H，Punie K，et al. Features of durable response and treatment efficacy for capecitabine monotherapy in advanced breast cancer：real-world evidence from a large single-centre cohort ［J］. J Cancer Res Clin Oncol，2021，147（4）：1041-1048.
|
| ［52］ |
Metzger Filho O，Giobbie-Hurder A，Mallon E，et al. Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial ［J］. J Clin Oncol，2015，33（25）：2772-2779.
|
| ［53］ |
van de Water W，Fontein DB，van Nes JG，et al. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer-a TEAM study analysis ［J］. Eur J Cancer，2013，49（2）：297-304.
|
| ［54］ |
van Maaren MC，de Munck L，Strobbe LJA，et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands：A large population-based study ［J］. Int J Cancer，2019，144（2）：263-272.
|
| ［55］ |
Howell A，Cuzick J，Baum M，et al. Results of the ATAC（arimidex，tamoxifen，alone or in combination）trial after completion of 5 years' adjuvant treatment for breast cancer ［J］. Lancet，2005，365（9453）：60-62.
|
| ［56］ |
Strasser-Weippl K，Sudan G，Ramjeesingh R，et al. Outcomes of invasive ductal（ID）or invasive lobular（IL）early stage breast cancer in women treated with anastrozole or exemestane in the Canadian cancer trials Group MA. 27 ［J］. J Clin Oncol，2016，34（15 Suppl）：521.
|
| ［57］ |
Francis PA，Pagani O，Fleming GF，et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer ［J］. N Engl J Med，2018，379（2）：122-137.
|
| ［58］ |
Thomas M，Kelly ED，Abraham J，et al. Invasive lobular breast cancer：a review of pathogenesis，diagnosis，management，and future directions of early stage disease ［J］. Semin Oncol，2019，46（2）：121-132.
|
| ［59］ |
Ellis MJ，Suman VJ，Hoog J，et al. Randomized phase Ⅱ neoadjuvant comparison between letrozole，anastrozole，and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer：clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031 ［J］. J Clin Oncol，2011，29（17）：2342-2349.
|
| ［60］ |
Dixon JM，Renshaw L，Dixon J，et al. Invasive lobular carcinoma：response to neoadjuvant letrozole therapy ［J］. Breast Cancer Res Treat，2011，130（3）：871-877.
|
| ［61］ |
O'Connor DJ，Davey MG，Barkley LR，et al. Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery-a systematic review and meta-analysis ［J］. Breast，2022，61:1-10.
|
| ［62］ |
Chiba A，Hoskin TL，Heins CN，et al. Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer：a national cancer data base study ［J］. Ann Surg Oncol，2017，24（2）：418-424.
|
| ［63］ |
Thornton MJ，Williamson HV，Westbrook KE，et al. Neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in node-positive invasive lobular carcinoma ［J］. Ann Surg Oncol，2019，26（10）：3166-3177.
|
| ［64］ |
Johnston SRD, Harbeck N, Hegg R，et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+， HER2-， node-positive， high-risk， early breast Cancer （monarchE） ［J］. J Clin Oncol，2020，38（34）：3987-3998.
|
| ［65］ |
Slamon D，Lipatov O，Nowecki Z，et al. Ribociclib plus endocrine therapy in early breast cancer ［J］. N Engl J Med，2024，390（12）：1080-1091.
|
| ［66］ |
Finn RS，Martin M，Rugo HS，et al. Palbociclib and letrozole in advanced breast cancer ［J］. N Engl J Med，2016，375（20）：1925-1936.
|
| ［67］ |
Gao JJ，Cheng J，Bloomquist E，et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive，HER2-negative，advanced or metastatic breast cancer：a US Food and Drug Administration pooled analysis ［J］. Lancet Oncol，2020，21（2）：250-260.
|
| ［68］ |
Gao JJ，Cheng J，Prowell TM，et al. Overall survival in patients with hormone receptor-positive，HER2-negative，advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant：a US Food and Drug Administration pooled analysis ［J］. Lancet Oncol，2021，22（11）：1573-1581.
|
| ［69］ |
Yu J，Dabbs DJ，Shuai Y，et al. Classical-type invasive lobular carcinoma with HER2 overexpression：clinical，histologic，and hormone receptor characteristics ［J］. Am J Clin Pathol，2011，136（1）：88-97.
|
| ［70］ |
Lal P，Tan LK，Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3655 invasive breast carcinomas ［J］. Am J Clin Pathol，2005，123（4）：541-546.
|
| ［71］ |
Metzger-Filho O，Procter M，de Azambuja E，et al. Magnitude of trastuzumab benefit in patients with HER2-positive，invasive lobular breast carcinoma：results from the HERA trial ［J］. J Clin Oncol，2013，31（16）：1954-1960.
|
| ［72］ |
Gianni L，Pienkowski T，Im YH，et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced，inflammatory，or early-stage HER2-positive breast cancer（NeoSphere）：a multicentre，open-label，phase 2 randomised trial ［J］. Lancet Oncol，2016，17（6）：791-800.
|
| ［73］ |
Zhang H，Moisini I，Ajabnoor RM，et al. Frequency，clinicopathologic characteristics，and follow-up of HER2-positive nonpleomorphic invasive lobular carcinoma of the breast ［J］. Am J Clin Pathol，2020，153（5）：583-592.
|
| ［74］ |
Huang X，Chen H，Ding Q，et al. Clinicopathological features of and neoadjuvant therapy for human epidermal growth factor receptor 2-positive classic invasive lobular carcinoma ［J］. Hum Pathol，2021，117：51-59.
|
| ［75］ |
Freitag CE，Mei P，Wei L，et al. Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas：focusing on clinically actionable genetic alterations ［J］. Hum Pathol，2020，102：94-103.
|
| ［76］ |
Uchida S，Kojima T，Sugino T. Clinicopathological features，tumor mutational burden，and tumour-infiltrating lymphocyte interplay in ERBB2-mutated breast cancer：in silico analysis ［J］. Pathol Oncol Res，2021，27：633243.
|
| ［77］ |
Ma CX，Luo J，Freedman RA，et al. The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2-mutated，non-amplified metastatic breast cancer ［J］. Clin Cancer Res，2022，28（7）：1258-1267.
|
| ［78］ |
Jhaveri K，Eli LD，Wildiers H，et al. Neratinib+fulvestrant+trastuzumab for HR-positive，HER2-negative，HER2-mutant metastatic breast cancer：outcomes and biomarker analysis from the SUMMIT trial ［J］. Ann Oncol，2023，34（10）：885-898.
|
| ［79］ |
Mittendorf EA，Zhang H，Barrios CH，et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer（IMpassion031）：a randomised，double-blind，phase 3 trial ［J］. Lancet，2020，396（10257）：1090-1100.
|
| ［80］ |
Rugo HS，Delord JP，Im SA，et al. Safety and antitumor activity of pembrolizumab in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer ［J］. Clin Cancer Res，2018，24（12）：2804-2811.
|
| ［81］ |
Bajrami I，Marlow R，van de Ven M，et al. E-Cadherin/ROS1 inhibitor synthetic lethality in breast cancer ［J］. Cancer Discov，2018，8（4）：498-515.
|
| ［82］ |
Agostinetto E， Nader-Marta G， Paesmans M， et al. ROSALINE： a phase Ⅱ， neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast ［J］. Future Oncol， 2022， 18（22）： 2383-2392.
|
| ［83］ |
Luveta J，Parks RM，Heery DM，et al. Invasive lobular breast cancer as a distinct disease：implications for therapeutic strategy ［J］. Oncol Ther，2020，8（1）：1-11.
|